Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Prognostic value of radiographically defined extranodal extension in human papillomavirus‐associated locally advanced oropharyngeal carcinoma
Tian, Sibo , Ferris, Matthew J. , Switchenko, Jeffrey M. , Magliocca, Kelly R. , Cassidy, Richard J. , Jhaveri, Jaymin , Baugnon, Kristen L. , Hudgins, P.A. , Curran, Walter J. , Beitler, Jonathan J. , Hudgins, Patricia A , Kendi, Ayse T K, Patel, Mihir R , Saba, Nabil F , Beitler, Jonathan J , Switchenko, Jeffrey , Aiken, Ashley H. , Kendi, A. Tuba , Saba, Nabil F.

Mayo Clinic

Head & Neck | May 2, 2019 | Volume: 41 | Issue: 9 | Pages: 3056-3063

10.1002/hed.25791 | PMID 31046181 Get It

AbstractBackgroundPathologic extranodal extension (ENE) has traditionally guided the management of head and neck cancers. The prognostic value of radiographic ENE (rENE) in human papillomavirus (HPV)‐associated oropharyngeal squamous cell carcinoma (HPV + OPX) is uncertain.MethodsPatients with HPV + OPX with adequate pretreatment radiographic nodal evaluation from a single institution were analyzed. rENE status was determined by neuroradiologists' at time of diagnosis. Distant metastasis‐free survival (DMFS), overall survival (OS), and locoregional recurrence‐free survival (LRFS) were estimated using Kaplan‐Meier methods. Cox proportional hazards models were fit to assess the impact of rENE on survival endpoints.ResultsHundred sixty‐eight patients with OPX + squamous cell carcinomas diagnosed between April 2008 and December 2014 were included for analysis with median follow‐up of 3.3 years. Eighty‐eight percent of patients received concurrent chemoradiotherapy. rENE was not prognostic; its presence in patients with HPV + OPX did not significantly impact OS, LRFS, or DMFS.ConclusionsIn patients with HPV + OPX, rENE was not significantly associated with OS, LRFS, or DMFS.
Joint Outcomes Following Surgery for Superior Tibiofibular Joint-Associated Peroneal Intraneural Ganglion Cysts
Wilson, Thomas J. , Stone, Jonathan J. , Howe, B. Matthew, Rock, Michael G., Spinner, Robert J.

Mayo Clinic

Neurosurgery | April 30, 2019 | Volume: 86 | Issue: 3 | Pages: 383-390

10.1093/neuros/nyz205 | PMID 31215635 Get It

Abstract BACKGROUND Intraneural ganglion cysts are joint-connected, with the primary pathology residing in the associated joint. For peroneal intraneural ganglion cysts, the surgical strategy can include resection of the synovial surface of the superior tibiofibular joint (STFJ). However, the rate of instability postoperatively is unclear. OBJECTIVE To evaluate the rate of STFJ instability, following surgery for peroneal intraneural ganglion cysts. The second goal of the study was to assess the relationship between volume of resection of the STFJ and risk of extraneural recurrence. METHODS We performed a retrospective analysis of a cohort of patients with peroneal intraneural ganglion cysts. We analyzed clinical factors, including recurrence, and assessed the rate of postoperative STFJ instability. We created 3-dimensional models of the STFJ pre- and postoperatively to compare the volume of resection in recurrent cases and nonrecurrent cases using a case-control design. RESULTS The total cohort consisted of 65 subjects. No patient had evidence of radiological or clinical instability of the STFJ postoperatively. Extraneural radiological recurrence occurred in 6 (9%) patients. No intraneural recurrences were observed. The average volume of resection for patients with recurrence was 1349 mm 3 (SD = 1027 mm 3 ) vs 3018 mm 3 (SD = 1433 mm 3 ) in controls that did not have a recurrence ( P = .018). CONCLUSION This study supports performing an aggressive STFJ resection to minimize the risk of extraneural recurrence. Superior tibiofibular joint resection is not associated with postoperative joint instability. A smaller volume resection is correlated with recurrence risk.
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas
Jones, Robin L. , Chawla, Sant P. , Attia, Steven , Schöffski, Patrick , Gelderblom, Hans , Cesne, Axel Le, Patel, Shreyaskumar , Wagner, Andrew J. , Heyburn, John, Weil, Susan C., Viele, Kert , Maki, Robert G. , Maki, Robert G , Jones, Robin L , Gelderblom, Hans , Chmielowski, Bartosz , Tine, Brian A. Van , Trent, Jonathan C. , Chugh, Rashmi , Wang, Wenquan

Mayo Clinic

Cancer | April 30, 2019 | Volume: 125 | Issue: 14 | Pages: 2445-2454

10.1002/cncr.32084 | PMID 31034598 Get It

Background Ontuxizumab, a humanized monoclonal antibody, targets endosialin (tumor endothelial marker 1 [TEM‐1] or CD248), which is expressed on sarcoma cells and is believed to be involved in tumor angiogenesis. This is the first trial to evaluate ontuxizumab in patients with sarcoma. Methods Part 1 was an open‐label, dose‐finding, safety lead‐in: 4, 6, or 8 mg/kg with gemcitabine and docetaxel (G/D; 900 mg/m 2 gemcitabine on days 1 and 8 and 75 mg/m 2 docetaxel on day 8). In part 2, patients were randomized in a double‐blind fashion in 2:1 ratio to ontuxizumab (8 mg/kg) or a placebo with G/D. Randomization was stratified by 4 histological cohorts. Results In part 2 with 209 patients, no significant difference in progression‐free survival between ontuxizumab plus G/D (4.3 months; 95% confidence interval [CI], 2.7‐6.3 months) and the placebo plus G/D (5.6 months; 95% CI, 2.6‐8.3 months) was observed ( P = .67; hazard ratio [HR], 1.07; 95% CI, 0.77‐1.49). Similarly, there was no significant difference in median overall survival between the 2 groups: 18.3 months for the ontuxizumab plus G/D group (95% CI, 16.2‐21.1 months) and 21.1 months for the placebo plus G/D group (95% CI, 14.2 months to not reached; P = .32; HR, 1.23; 95% CI, 0.82‐1.82). No significant differences between the treatment groups occurred for any efficacy parameter by sarcoma cohort. The combination of ontuxizumab plus G/D was generally well tolerated. Conclusions Ontuxizumab plus G/D showed no enhanced activity over chemotherapy alone in soft‐tissue sarcomas, whereas the safety profile of the combination was consistent with G/D alone.
Management Reasoning: Implications for Health Professions Educators and a Research Agenda
Cook, David A. , Durning, Steven J. , Sherbino, Jonathan , Gruppen, Larry D.

Mayo Clinic

Academic Medicine | April 29, 2019 | Volume: 94 | Issue: 9 | Pages: 1310-1316

10.1097/acm.0000000000002768 | PMID 31460922 Get It

Substantial research has illuminated the clinical reasoning processes involved in diagnosis (diagnostic reasoning). Far less is known about the processes entailed in patient management (management reasoning), including decisions about treatment, further testing, follow-up visits, and allocation of limited resources. The authors’ purpose is to articulate key differences between diagnostic and management reasoning, implications for health professions education, and areas of needed research. Diagnostic reasoning focuses primarily on classification (i.e., assigning meaningful labels to a pattern of symptoms, signs, and test results). Management reasoning involves negotiation of a plan and ongoing monitoring/adjustment of that plan. A diagnosis can usually be established as correct or incorrect, whereas there are typically multiple reasonable management approaches. Patient preferences, clinician attitudes, clinical contexts, and logistical constraints should not influence diagnosis, whereas management nearly always involves prioritization among such factors. Diagnostic classifications do not necessarily require direct patient interaction, whereas management prioritizations require communication and negotiation. Diagnoses can be defined at a single time point (given enough information), whereas management decisions are expected to evolve over time. Finally, management is typically more complex than diagnosis. Management reasoning may require educational approaches distinct from those used for diagnostic reasoning, including teaching distinct skills (e.g., negotiating with patients, tolerating uncertainty, and monitoring treatment) and developing assessments that account for underlying reasoning processes and multiple acceptable solutions. Areas of needed research include if and how cognitive processes differ for management and diagnostic reasoning, how and when management reasoning abilities develop, and how to support management reasoning in clinical practice.
Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest
Werf, Christian van der , Lieve, Krystien V.V. , Bos, J. Martijn , Lane, Conor M. , Rosés‐Noguer, Ferran , Aiba, Takeshi , Wada, Yuko , Ingles, Jodie , Leren, Ida S. , Rudic, Boris , Maltret, Alice , Sacher, Frédéric , Skinner, Jonathan R. , Roston, Thomas M. , Tfelt‐Hansen, Jacob , Swan, Heikki, Robyns, Tomas , Ohno, Seiko , Roberts, Jason D. , Berg, Maarten P. van den , Kammeraad, Janneke A.E. , Blom, Nico A, Behr, Elijah R. , Borggrefe, Martin , Haugaa, Kristina H. , Semsarian, Christopher , Horie, Minoru , Till, Janice, Ackerman, Michael J. , Wilde, Arthur A.M. , Horie, Minoru , Behr, Elijah Raphael , Bos, Johan M , Tfelt-Hansen, Jacob , Skinner, Jonathan R , van den Berg, Maarten P , Robyns, Tomas , Haugaa, Kristina , Wada, Yuko , van der Werf, Christian , Rosés-Noguer, Ferran , Denjoy, Isabelle , Aiba, Takeshi , Schwartz, Peter J. , Krahn, Andrew D. , Ohno, Seiko , Probst, Vincent , Kannankeril, Prince J. , Blom, Nico A. , Shimizu, Wataru , Leenhardt, Antoine , Ingles, Jodie , Lieve, Krystien V

Mayo Clinic

European Heart Journal | April 26, 2019 | Volume: 40 | Issue: 35 | Pages: 2953-2961

10.1093/eurheartj/ehz309 | PMID 31145795 Get It

Abstract Aims In patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), implantable cardioverter-defibrillator (ICD) shocks are sometimes ineffective and may even trigger fatal electrical storms. We assessed the efficacy and complications of ICDs placed in patients with CPVT who presented with a sentinel event of sudden cardiac arrest (SCA) while undiagnosed and therefore untreated. Methods and results We analysed 136 patients who presented with SCA and in whom CPVT was diagnosed subsequently, leading to the initiation of guideline-directed therapy, including β-blockers, flecainide, and/or left cardiac sympathetic denervation. An ICD was implanted in 79 patients (58.1%). The primary outcome of the study was sudden cardiac death (SCD). The secondary outcomes were composite outcomes of SCD, SCA, appropriate ICD shocks, and syncope. After a median follow-up of 4.8 years, SCD had occurred in three patients (3.8%) with an ICD and none of the patients without an ICD (P = 0.1). SCD, SCA, or appropriate ICD shocks occurred in 37 patients (46.8%) with an ICD and 9 patients (15.8%) without an ICD (P < 0.0001). Inappropriate ICD shocks occurred in 19 patients (24.7%) and other device-related complications in 22 patients (28.9%). Conclusion In previously undiagnosed patients with CPVT who presented with SCA, an ICD was not associated with improved survival. Instead, the ICD was associated with both a high rate of appropriate ICD shocks and inappropriate ICD shocks along with other device-related complications. Strict adherence to guideline-directed therapy without an ICD may provide adequate protection in these patients without all the potential disadvantages of an ICD.
Comparison of Patient‐Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT‐AF Registry
Perino, Alexander C., Shrader, Peter, Turakhia, Mintu P., Ansell, Jack E., Gersh, Bernard J., Fonarow, Gregg C., Go, Alan S., Kaiser, Daniel W., Hylek, Elaine M., Kowey, Peter R., Singer, Daniel E., Thomas, Laine, Steinberg, Benjamin A., Peterson, Eric D., Piccini, Jonathan P., Mahaffey, Kenneth W., Mahaffey, Kenneth W. , Turakhia, Mintu P. , Turakhia, Mintu P , Perino, Alexander C., Shrader, Peter, Ansell, Jack E., Gersh, Bernard J., Fonarow, Gregg C., Go, Alan S., Kaiser, Daniel W., Hylek, Elaine M., Kowey, Peter R., Singer, Daniel E., Thomas, Laine, Steinberg, Benjamin A., Peterson, Eric D., Piccini, Jonathan P.

Mayo Clinic

Journal of the American Heart Association | April 26, 2019 | Volume: 8 | Issue: 9 | Pages: No page available

10.1161/jaha.118.011205 | PMID 31023126 Get It

Background Patient satisfaction with therapy is an important metric of care quality and has been associated with greater medication persistence. We evaluated the association of patient satisfaction with warfarin therapy to other metrics of anticoagulation care quality and clinical outcomes among patients with atrial fibrillation ( AF ). Methods and Results Using data from the ORBIT ‐ AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry, patients were identified with AF who were taking warfarin and had completed an Anti‐Clot Treatment Scale ( ACTS ) questionnaire, a validated metric of patient‐reported burden and benefit of oral anticoagulation. Multivariate regressions were used to determine association of ACTS burden and benefit scores with time in therapeutic international normalized ratio range ( TTR ; both ≥75% and ≥60%), warfarin discontinuation, and clinical outcomes (death, stroke, major bleed, and all‐cause hospitalization). Among 1514 patients with AF on warfarin therapy (75±10 years; 42% women; CHA 2 DS 2 ‐ VAS c 3.9±1.7), those most burdened with warfarin therapy were younger and more likely to be women, have paroxysmal AF , and to be treated with antiarrhythmic drugs. After adjustment for covariates, ACTS burden scores were independent of TTR ( TTR ≥75%: odds ratio, 1.01 [95% CI , 0.99–1.03]; TTR ≥60%: odds ratio, 1.01 [95% CI , 0.98–1.05]), warfarin discontinuation (odds ratio, 0.99; 95% CI , 0.97–1.01), or clinical outcomes. ACTS benefit scores were also not associated with TTR , warfarin discontinuation, or clinical outcomes. Conclusions In a large registry of patients with AF taking warfarin, ACTS scores provided independent information beyond other traditional metrics of oral anticoagulation care quality and identified patient groups at high risk for dissatisfaction with warfarin therapy.
A novel muscle cramp scale (MCS) in amyotrophic lateral sclerosis (ALS)
Mitsumoto, Hiroshi , Chiuzan, Codruța , Gilmore, Madison , Zhang, Yuan , Ibagon, Camila , McHale, Brittany , Hupf, Jonathan , Oskarsson, Björn , Oskarsson, Björn

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | April 22, 2019 | Volume: 20 | Issue: 5-6 | Pages: 328-335

10.1080/21678421.2019.1603310 | PMID 31007059 Get It

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
Schneider, Benjamin , Boyer, Arnaud, Ciccolini, Joseph , Benzekry, Sébastien , Mochel, Jonathan P. , Mochel, Jonathan P , Barlési, Fabrice , Wang, Kenneth

Mayo Clinic

CPT: Pharmacometrics & Systems Pharmacology | April 20, 2019 | Volume: 8 | Issue: 8 | Pages: 577-586

10.1002/psp4.12415 | PMID 31004380 Get It

Bevacizumab‐pemetrexed/cisplatin ( BEV ‐ PEM / CIS ) is a first‐line therapeutic for advanced nonsquamous non‐small cell lung cancer. Bevacizumab potentiates PEM / CIS cytotoxicity by inducing transient tumor vasculature normalization. BEV ‐ PEM / CIS has a narrow therapeutic window. Therefore, it is an attractive target for administration schedule optimization. The present study leverages our previous work on BEV ‐ PEM / CIS pharmacodynamic modeling in non‐small cell lung cancer–bearing mice to estimate the optimal gap in the scheduling of sequential BEV ‐ PEM / CIS . We predicted the optimal gap in BEV ‐ PEM / CIS dosing to be 2.0 days in mice and 1.2 days in humans. Our simulations suggest that the efficacy loss in scheduling BEV ‐ PEM / CIS at too great of a gap is much less than the efficacy loss in scheduling BEV ‐ PEM / CIS at too short of a gap.